Buchumschlag

Who Wins the Battle Against Obesity? A Network Meta‐Analysis Comparing Tirzepatide and Semaglutide

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Julia C. Bernardi, Deivyd V. S. Cavalcante, Ramon Huntermann, Maria E. Molinari, Luana Z. Zanon, Jacinthe Khater, Victor A. Gomez, Caroline O. Fischer‐Bacca
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2026
Schlagworte:	Journal of Diabetes
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity
von: Andreea Ciudin, et al.
Veröffentlicht: (2026)

Comment on ‘Semaglutide and Tirzepatide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World ( STEER )’
von: Chih‐Yuan Wang
Veröffentlicht: (2026)

Real‐World Cardiovascular Outcomes of Obesity Treatment With Tirzepatide Versus Semaglutide in Non‐Diabetic Adults
von: Mai Katsura, et al.
Veröffentlicht: (2026)

Interpreting Post‐Discontinuation Trajectories After Semaglutide or Tirzepatide
von: Man Sun, et al.
Veröffentlicht: (2026)

Effect of Tirzepatide on Heart Failure in Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Meta‐Analysis
von: Yi‐Meng He, et al.
Veröffentlicht: (2025)

Association of Tirzepatide With Kidney Parameters in Participants With Obesity and Prediabetes From SURMOUNT ‐1 Over 176 Weeks
von: Hiddo J. L. Heerspink, et al.
Veröffentlicht: (2026)

The cost‐utility and budget impact analyses of Tirzepatide versus once‐weekly Semaglutide as add‐on therapy to metformin in patients with type 2 diabetes mellitus in China
von: Sihua Wang, et al.
Veröffentlicht: (2025)

Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population‐Adjusted Indirect Treatment Comparison
von: Wojciech Michalak, et al.
Veröffentlicht: (2026)

Efficacy, Safety and PK of Once‐Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model‐Informed Drug Development Approach
von: Rune Viig Overgaard, et al.
Veröffentlicht: (2026)

Six‐Month Real‐World Effectiveness, Persistence and Safety of Low‐to‐Moderate Dose Tirzepatide in Adults With Obesity: A Multicentre Observational Study
von: Nikolaos Angelopoulos, et al.
Veröffentlicht: (2026)

Effect of Tirzepatide on Health‐Related Quality of Life in Japanese Patients With Obesity Disease: Patient‐Reported Outcomes From the SURMOUNT ‐J Study
von: Hiroaki Masuzaki, et al.
Veröffentlicht: (2026)

Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach
von: Anders Strathe, et al.
Veröffentlicht: (2026)

SEMASEARCH Study Design: Real‐World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials
von: Pierre Bel Lassen, et al.
Veröffentlicht: (2026)

Comparative effectiveness of continuous positive airway pressure and glucagon‐like peptide‐1 receptor agonists in obstructive sleep apnea: A network meta‐analysis of randomised trials
von: Gaspar R. Chiappa, et al.
Veröffentlicht: (2026)

Comment on ‘Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach’
von: Vijay Kumar K. V., et al.
Veröffentlicht: (2026)

Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis
von: Ali Abdullah, et al.
Veröffentlicht: (2025)

Tirzepatide in the NHS : The known unknowns of treating obesity at a national scale
von: Ashley Kieran Clift, et al.
Veröffentlicht: (2025)

Tirzepatide and health‐related quality of life in adults with obesity or overweight: Results from the SURMOUNT ‐3 phase 3 randomized trial
von: Theresa Hunter Gibble, et al.
Veröffentlicht: (2025)

SemaGBA : A System Dynamics Model of the Semaglutide‐Responsive Gut‐Brain Axis A Model of How the Brain and Semaglutide Regulate Appetite and Weight
von: Vivan C. W. Kennis, et al.
Veröffentlicht: (2026)

Semaglutide and MASH resolution: A pooled analysis of recent trials
von: Alaa Abdrabou Abouelmagd, et al.
Veröffentlicht: (2025)

Real‐World Persistence and Characteristics of Type 2 Diabetes Patients Prescribed Semaglutide in Scotland
von: David Alexander Dickie, et al.
Veröffentlicht: (2025)

Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real‐World: Results From the SCORE—Clinical ASCVD Study
von: Michael G. Nanna, et al.
Veröffentlicht: (2026)

Tirzepatide‐induced body composition changes: Implications from the SURPASS ‐3 MRI substudy
von: I‐Weng Yen, et al.
Veröffentlicht: (2026)

Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study
von: Mathieu Alissou, et al.
Veröffentlicht: (2025)

Brain Serotonin Transporter Is Elevated in Obesity: Bayesian and Frequentist Meta‐Analyses
von: Kyoungjune Pak
Veröffentlicht: (2026)

Interpreting Lean Mass Changes During Tirzepatide‐Induced Weight Loss: Beyond Quantitative Metrics
von: Tuba Uyanık
Veröffentlicht: (2026)

Tirzepatide shown to be effective at reducing sleep disturbances in patients with obstructive sleep apnoea
von: Iskandar Idris
Veröffentlicht: (2024)

Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison
von: Emily R. Hankosky, et al.
Veröffentlicht: (2025)

Genetic Variants in the Fat Mass and Obesity‐Associated Gene and Risk of Obesity/Overweight in Children and Adolescents: A Systematic Review and Meta‐Analysis
von: Maryam Eghbali, et al.
Veröffentlicht: (2024)

Semaglutide and Cardiovascular Outcomes According to Baseline Aspirin Use: Analyses of the SOUL and SELECT Trials
von: Dirk Müller‐Wieland, et al.
Veröffentlicht: (2026)

Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world ( STEER )
von: Lauren Wilson, et al.
Veröffentlicht: (2026)

Semaglutide beyond weight loss: Mechanistic insights and functional paradoxes from the SEMALEAN study
von: Shambo S. Samajdar, et al.
Veröffentlicht: (2025)

ForePass outperforms Semaglutide in weight control, glucose metabolism, and gut microbiota in swine
von: Sara Russo, et al.
Veröffentlicht: (2025)

Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism
von: Nadan Gregorič, et al.
Veröffentlicht: (2024)

Semaglutide improves treatment satisfaction and eating behaviour in Japanese patients with type 2 diabetes mellitus
von: Yusuke Baba, et al.
Veröffentlicht: (2024)

Semaglutide and cardiovascular risk in type 1 diabetes: A predictive modelling analysis in a double‐blind, randomised, placebo‐controlled cross‐over trial
von: Luxcia Kugathasan, et al.
Veröffentlicht: (2026)

The 2023 WCIRDC: Obesity
von: Zachary T. Bloomgarden
Veröffentlicht: (2024)

Mechanisms of diabetic cardiomyopathy: Focus on inflammation
von: Myriam Bellemare, et al.
Veröffentlicht: (2025)

Estimated Oral Semaglutide Exposure Has Distinct Relationships With Glycaemic Response, Weight Loss and Gastrointestinal Tolerability
von: Gian Paolo Fadini, et al.
Veröffentlicht: (2026)

Semaglutide attenuates diabetic retinopathy progression via ameliorating retinal vasculopathy and oxidative stress in vivo and in vitro
von: Xiao Cheng, et al.
Veröffentlicht: (2025)